US Patent

US10836755 — Cardiac sarcomere inhibitors

Method of Use · Assigned to Cytokinetics Inc · Expires 2039-01-18 · 13y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds of Formula (I) and their pharmaceutically acceptable salts, as well as compositions and methods using these compounds.

USPTO Abstract

Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Z, B, R 1 , R 2 , R 3 , G 1 , G 2 , and G 3 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4371 —
U-4371 —
U-4371 —
U-4371 —

Patent Metadata

Patent number
US10836755
Jurisdiction
US
Classification
Method of Use
Expires
2039-01-18
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Cytokinetics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.